REFERENCES
- Kennedy J, Coyne J, Sclar D. Drug affordability and prescription noncompliance in the United States: 1997–2002. Clin Ther 2004; 26(4)607–14
- Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med 1985; 21(10)1063–69
- Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993; 153(16)1863–68
- Olshaker JS, Barish RA, Naradzay JF, et al. Prescription noncompliance: contribution to emergency department visits and cost. J Emerg Med 1999; 17(5)909–12
- Mitka M. Forecast for U.S. uninsured remains gloomy. JAMA 2004; 291(19)2305–06
- SAS/STAT User's Guide, Version 6 Fourth. Cary, SAS Institute. 1988; 1634
- Hsia J, Aragaki A, Bloch M, et al. Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiation observational study. Am J Cardiol 2004; 93(6)673–78
- Baune BT, Aljeesh Y, Bender R. Factors of non-compliance with the therapeutic regimen among hypertensive men and women: a case-control study to investigate risk factors of stroke. Eur J Epidemiol 2005; 20(5)411–19
- Bech P. Quality of life measurements for patients taking which drugs? Clinical PCASEE perspective. Pharmacoeconomics 1995; 7(2)141–51
- Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart Journal 2005; 149(1)33–45
- Surwit RS, van Tilburg MA, Zucker N, et al. Stress management improves long-term glycemic control in type II diabetes. Diabetes Care 2002; 25(1)30–4
- Rosmond R. Role of stress in the pathogenesis of metabolic syndrome. Pscyhoneuroendocrinology 2005; 30(1)1–10
- ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA 2002; 288(23)2981–2997
- Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80(5)437–41
- Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411)757–67
- Kuo Y, Raji MA, Markides KS, et al. Inconsistent use of diabetes medications, diabetes, complications, and mortality in older Mexican Americans over a 7 year period. Diabetes Care 2003; 26(11)3054–60